New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer

por Weise, Amy M, Gadgeel, Shirish
Publicado 2014

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer

por Bardia, Aditya, Kaklamani, Virginia, Wilks, Sharon, Weise, Amy, Richards, Donald, Harb, Wael, Osborne, Cynthia, Wesolowski, Robert, Karuturi, Meghan, Conkling, Paul, Bagley, Rebecca G., Wang, Yamei, Conlan, Maureen G., Kabos, Peter
Publicado 2021

Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases

por In, Gino K., Poorman, Kelsey, Saul, Michelle, O’Day, Steven, Farma, Jeffrey M., Olszanski, Anthony J., Gordon, Michael S., Thomas, Jacob S., Eisenberg, Burton, Flaherty, Lawrence, Weise, Amy, Daveluy, Steven, Gibney, Geoffrey, Atkins, Michael B., Vanderwalde, Ari
Publicado 2020

Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer

por Tsimberidou, Apostolia-Maria, Shaw, Jamie V., Juric, Dejan, Verschraegen, Claire, Weise, Amy M., Sarantopoulos, John, Lopes, Gilberto, Nemunaitis, John, Mita, Monica, Park, Haeseong, Ellers-Lenz, Barbara, Tian, Hui, Xiong, Wenyuan, Kaleta, Remigiusz, Kurzrock, Razelle
Publicado 2021

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

por Naing, Aung, Infante, Jeffrey, Goel, Sanjay, Burris, Howard, Black, Chelsea, Marshall, Shannon, Achour, Ikbel, Barbee, Susannah, May, Rena, Morehouse, Chris, Pollizzi, Kristen, Song, Xuyang, Steele, Keith, Elgeioushi, Nairouz, Walcott, Farzana, Karakunnel, Joyson, LoRusso, Patricia, Weise, Amy, Eder, Joseph, Curti, Brendan, Oberst, Michael
Publicado 2019

A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma

por Shapiro, Geoffrey I., LoRusso, Patricia, Dowlati, Afshin, T. Do, Khanh, Jacobson, Caron A., Vaishampayan, Ulka, Weise, Amy, Caimi, Paolo F., Eder, Joseph Paul, French, Christopher A., Labriola-Tompkins, Emily, Boisserie, Frédéric, Pierceall, William E., Zhi, Jianguo, Passe, Sharon, DeMario, Mark, Kornacker, Martin, Armand, Philippe
Publicado 2020

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

por Sanborn, Rachel E, Pishvaian, Michael J, Callahan, Margaret K, Weise, Amy, Sikic, Branimir I, Rahma, Osama, Cho, Daniel C, Rizvi, Naiyer A, Sznol, Mario, Lutzky, Jose, Bauman, Julie E, Bitting, Rhonda L, Starodub, Alexander, Jimeno, Antonio, Reardon, David A, Kaley, Thomas, Iwamoto, Fabio, Baehring, Joachim M, Subramaniam, Deepa S, Aragon-Ching, Jeanny B, Hawthorne, Thomas R, Rawls, Tracey, Yellin, Michael, Keler, Tibor
Publicado 2022

Identifying treatment options for BRAF(V600) wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial

por LoRusso, Patricia M., Sekulic, Aleksandar, Sosman, Jeffrey A., Liang, Winnie S., Carpten, John, Craig, David W., Solit, David B., Bryce, Alan H., Kiefer, Jeffrey A., Aldrich, Jessica, Nasser, Sara, Halperin, Rebecca, Byron, Sara A., Pilat, Mary Jo, Boerner, Scott A., Durecki, Diane, Hendricks, William P. D., Enriquez, Daniel, Izatt, Tyler, Keats, Jonathan, Legendre, Christophe, Markovic, Svetomir N., Weise, Amy, Naveed, Fatima, Schmidt, Jessica, Basu, Gargi D., Sekar, Shobana, Adkins, Jonathan, Tassone, Erica, Sivaprakasam, Karthigayini, Zismann, Victoria, Calvert, Valerie S., Petricoin, Emanuel F., Fecher, Leslie Anne, Lao, Christopher, Eder, J. Paul, Vogelzang, Nicholas J., Perlmutter, Jane, Gorman, Mark, Manica, Barbara, Fox, Lisa, Schork, Nicholas, Zelterman, Daniel, DeVeaux, Michelle, Joseph, Richard W., Cowey, C. Lance, Trent, Jeffrey M.
Publicado 2021